Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
Authors:
Open Access
- 5 August 2019
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 104 (4) , 493-499
Abstract
Background/Aims Prospective data on switching anti-vascular endothelial growth factors in patients with neovascular age-related macular degeneration (nAMD) who have previously shown no/partial response are limited. This prospective study assessed the effect of switching from aflibercept to ranibizumab on anatomical and functional outcomes in patients with persistent/recurrent disease activity. Methods SAFARI (NCT02161575) was a 6-month, prospective, single-arm study conducted in the UK and Germany. Patients, meeting strict eligibility criteria for one of two subgroups (primary treatment failure or suboptimal treatment response), received 3 monthly intravitreal ranibizumab injections (0.5 mg). Thereafter, ranibizumab was administered pro re nata at monthly visits. The primary endpoint was change from baseline (CfB) to day 90 in central subfield retinal thickness (CSRT). Best-corrected visual acuity (BCVA) and retinal morphology parameters were assessed. Results One hundred patients were enrolled (primary treatment failure, 1; suboptimal treatment response, 99). In the overall population, there was a significant CfB in median CSRT of −30.75 µm (95% CI −59.50,–20.50; pConclusion Switching from aflibercept to ranibizumab led to a significant improvement in CSRT, with ~60% experiencing stabilised/improved BCVA. Therefore, patients with nAMD who have shown a suboptimal response to aflibercept may benefit from switching to ranibizumab.Keywords
Funding Information
- Novartis Pharmaceuticals UK Limited
This publication has 24 references indexed in Scilit:
- Prevalence of Age-Related Macular Degeneration in EuropeOphthalmology, 2017
- Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseasesGraefe's Archive for Clinical and Experimental Ophthalmology, 2017
- Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive reviewDrug Design, Development and Therapy, 2016
- Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA studyBritish Journal of Ophthalmology, 2016
- CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENTRetina, 2016
- Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practiceGraefe's Archive for Clinical and Experimental Ophthalmology, 2015
- Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)British Journal of Ophthalmology, 2014
- Neovascular Age-Related Macular DegenerationOphthalmologica, 2012
- Limitations of the Randomized Controlled Trial in Evaluating Population-Based Health InterventionsAmerican Journal of Preventive Medicine, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006